GlassScriptPhysician profile
Cayla E Schnider
NPI 1457800070
$6,474.03
in general payments reported to CMS, 2019-2025
57 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $732 · 2022: $1,368 · 2023: $1,574 · 2024: $1,764 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,233 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,233.20 |
| Education | $141.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $699.98 | 2021-2025 | |
| Seagen INC. | $386.91 | 2021-2025 | Padcev, Tukysa, Adcetris |
| Janssen Biotech, INC. | $356.15 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $355.98 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $352.39 | 2023-2025 | |
| Abbvie INC. | $299.13 | 2022-2025 | |
| Incyte Corporation | $285.78 | 2021-2024 | Jakafi |
| Daiichi Sankyo INC. | $252.37 | 2021-2025 | Enhertu, Injectafer |
| Myriad Genetic Laboratories, INC. | $218.18 | 2022-2024 | Mychoice Cdx, Myrisk |
| Regeneron Healthcare Solutions, INC. | $217.17 | 2022-2024 | Libtayo |
| Amgen INC. | $202.89 | 2021-2023 | Kyprolis, Blincyto |
| Astrazeneca Pharmaceuticals LP | $201.10 | 2021-2024 | Calquence, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $199.71 | 2022-2024 | Ninlaro, Fruzaqla |
| Genzyme Corporation | $177.63 | 2021-2025 | |
| Eisai INC. | $166.44 | 2021-2025 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $153.92 | 2021-2025 | Padcev, Xtandi |
| Genentech USA, INC. | $142.60 | 2021-2024 | Lunsumio, Polivy, Columvi |
| Beigene USA, INC. | $132.52 | 2022-2024 | Brukinsa |
| Stemline Therapeutics INC. | $132.25 | 2023-2025 | Orserdu, Elzonris |
| Bayer Healthcare Pharmaceuticals INC. | $110.04 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $100.45 | 2023-2024 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $96.66 | 2021-2025 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $92.25 | 2023-2025 | Fotivda |
| Glaxosmithkline, LLC. | $80.70 | 2021-2025 | Ojjaara |
| Celgene Corporation | $74.53 | 2021-2024 | Reblozyl, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $69.03 | 2021-2023 | Opdivo |
| Exelixis INC. | $67.65 | 2021-2024 | Cabometyx |
| Karyopharm Therapeutics INC. | $60.79 | 2022-2024 | Xpovio |
| Immunogen, INC. | $53.07 | 2024 | Elahere |
| Mirati Therapeutics, INC. | $50.95 | 2024 | Krazati |
| Lilly USA, LLC | $48.45 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Jazz Pharmaceuticals INC. | $47.78 | 2024 | |
| Gilead Sciences, INC. | $41.19 | 2022-2023 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $40.77 | 2025 | Onivyde |
| Pharmacyclics LLC, An Abbvie Company | $38.63 | 2021-2023 | Imbruvica |
| Geron Corporation | $37.26 | 2025 | Rytelo |
| Epizyme, INC. | $32.34 | 2021 | |
| Medtronic, INC. | $31.38 | 2024 | Osteocool Rf Ablation System |
| Sun Pharmaceutical Industries INC. | $30.10 | 2022 | |
| Organon LLC | $28.08 | 2023 | Ontruzant |
| Beone Medicines USA, INC. | $24.84 | 2025 | Brukinsa |
| Kite Pharma, INC. | $24.34 | 2025 | Yescarta |
| Caris Mpi, INC. | $22.40 | 2025 | Mi Cancer Seek |
| Foundation Medicine, INC. | $22.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.46 | 2025 | Erleada |
| Sobi, INC | $19.61 | 2024 | |
| Fresenius Kabi USA, LLC | $19.39 | 2025 | Stimufend |
| Genmab U.S., INC. | $19.30 | 2023 | Epkinly |
| Blueprint Medicines Corporation | $18.30 | 2021 | |
| Mylan Institutional INC. | $18.10 | 2021 | |
| Acrotech Biopharma INC. | $17.03 | 2024 | Beleodaq |
| Array Biopharma INC | $16.39 | 2025 | Mektovi, Braftovi, Tukysa |
| Servier Pharmaceuticals LLC | $16.04 | 2022 | |
| Adc Therapeutics America, INC. | $15.28 | 2022 | |
| Pear Therapeutics (US), INC. | $11.98 | 2022 | |
| Emmaus Medical, INC. | $11.83 | 2021 | |
| Acceleron Pharma, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cayla Schnider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.